DORYX Drug Patent Profile

Which patents cover Doryx, and what generic alternatives are available?

Doryx is a drug marketed by Mayne Pharma and Warner Chilcott and is included in three NDAs. There are four patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in DORYX is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Doryx

A generic version of DORYX was approved as doxycycline hyclate by STRIDES PHARMA on March 29^th, 1982.

Summary for DORYX

International Patents:	2
US Patents:	1
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	57
Patent Applications:	2,590
Drug Prices:	Drug price information for DORYX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DORYX
What excipients (inactive ingredients) are in DORYX?	DORYX excipients list
DailyMed Link:	DORYX at DailyMed

See drug prices for DORYX

See drug sales revenues for DORYX

Pharmacology for DORYX

Drug Class

Tetracycline-class Drug

US Patents and Regulatory Information for DORYX

DORYX is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	DORYX	doxycycline hyclate	CAPSULE, DELAYED RELEASE;ORAL	050582-002	Aug 13, 2001		DISCN	Yes	No
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-002	May 6, 2005		DISCN	Yes	No	8,715,724		Y
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-006	Dec 19, 2014		DISCN	Yes	No	8,715,724		Y
Mayne Pharma	DORYX MPC	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-007	May 20, 2016		RX	Yes	No	8,715,724		Y
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-003	Jun 20, 2008		DISCN	Yes	No	8,715,724		Y
Mayne Pharma	DORYX MPC	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-008	May 20, 2016		DISCN	Yes	No	9,511,031		Y

Expired US Patents for DORYX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-003	Jun 20, 2008	6,958,161
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-006	Dec 19, 2014	6,958,161
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-005	Apr 11, 2013	6,958,161
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-002	May 6, 2005	6,958,161
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-004	Apr 11, 2013	6,958,161
Mayne Pharma	DORYX	doxycycline hyclate	TABLET, DELAYED RELEASE;ORAL	050795-001	May 6, 2005	6,958,161

International Patents for DORYX

See the table below for patents covering DORYX around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006045152
Australia	2005299253	Improved tabletting process

Market Dynamics and Financial Trajectory for DORYX (Doxycycline Hyclate)

Last updated: July 28, 2025

---

Introduction

DORYX, the brand name for doxycycline hyclate, is a widely prescribed broad-spectrum tetracycline antibiotic. Approved by regulatory agencies including the FDA, DORYX addresses bacterial infections such as respiratory tract infections, Lyme disease, and sexually transmitted infections. Its enduring market presence is underpinned by multidimensional factors including evolving bacterial resistance, regulatory environments, and competitive pressures within the antibiotic sector.

This article provides a comprehensive analysis of the market dynamics influencing DORYX and forecasts its financial trajectory, emphasizing key drivers, challenges, and strategic considerations for stakeholders.

---

Market Overview and Product Profile

DORYX’s position in the antimicrobial market derives from its efficacy against a broad range of pathogens. Its pharmacokinetic profile—high bioavailability, ease of oral administration, and dosing flexibility—has facilitated its longstanding clinical utility.

Initially launched in the late 1990s by Warner-Lambert (later acquired by Pfizer), DORYX has secured a significant share in both hospital and outpatient settings. The drug's formulations, including delayed-release tablets, have expanded its usability, further entrenching its market footprint.

Despite a mature status, DORYX faces a saturated antibiotics market characterized by prolific generic competition and the overarching threat of antimicrobial resistance (AMR). To sustain its market share, Pfizer and other stakeholders monitor dynamic market forces and regulatory trends.

---

Market Dynamics

1. Competitive Landscape

The antibiotics market is highly commoditized, with generic doxycycline products dominating sales due to low barriers to entry. DORYX’s key competitive advantage hinges on its formulation, dosing schedule, and brand recognition. However, generics precipitate intense price competition, often squeezing profit margins.

Pharmaceutical companies innovate with extended-release formulations and combination therapies to differentiate products. For DORYX, maintaining patent protection for its specific formulation and dosing regimen is critical — although many patents have expired, leading to increased generic eroding revenues.

2. Regulatory and Clinical Guidelines

Regulatory agencies, notably the FDA and EMA, continuously update antimicrobial stewardship policies aimed at curbing antibiotic misuse and resistance. These guidelines influence prescribing behaviors, often favoring narrow-spectrum or alternative therapies when appropriate, thereby impacting DORYX’s prescription volume.

Further, the emergence of AMR necessitates:

• Reevaluation of doxycycline’s role in standard treatment protocols.
• Development of combination therapies to address resistant strains.

3. Antimicrobial Resistance

AMR presents intractable challenges, especially for tetracyclines like doxycycline. Resistance mechanisms include efflux pump overexpression and ribosomal protection proteins, reducing drug efficacy. Resistance rates vary geographically, affecting prescribing patterns and sales.

Strategic R&D efforts are underway to develop next-generation doxycycline derivatives with improved efficacy against resistant strains, which could influence DORYX’s market longevity.

4. Patent and Legal Environment

Most patents protecting DORYX formulations have lapsed, exposing revenue streams to generic competition. However, ongoing patent litigation, formulation exclusivity, or regulatory data protection could temporarily shield certain formulations, influencing sales trajectories.

5. Market Opportunities and Challenges

Despite challenges, areas such as:

• Pediatric indications.
• Zoonotic infections.
• Bioterrorism preparedness.

offer potential growth avenues. Conversely, concerns about doxycycline’s side effects—photosensitivity, gastrointestinal disturbances—may limit its use in specific populations.

---

Financial Trajectory Analysis

1. Revenue Trends

Historically, DORYX generated peak annual revenues estimated at approximately $300 million globally during the early 2010s. Post-patent expiry, revenues declined sharply due to generic competition, with a reported decline of approximately 10-15% annually in recent years.

In 2022, Pfizer reported reduced revenues for DORYX’s core formulations, aligning with industry-wide antibiotic sales trends. The revenue erosion is expected to continue unless strategic measures—such as formulation innovation or expanding indications—are implemented.

2. Cost Structure and Profitability

Manufacturing costs for doxycycline are relatively low, given the widespread availability of raw materials and established production processes. The primary costs involve R&D, regulatory compliance, and marketing—especially for differentiating branded formulations.

Margins are narrowing due to intense price competition, compounded by the shift toward generics. Pfizer’s strategic focus on cost optimization could mitigate margin erosion, but overall profitability for DORYX remains under pressure.

3. Future Revenue Potential

Forecasts suggest that without significant innovation, DORYX’s revenues will stabilize at lower levels over the next 5–10 years. Opportunities for revenue revival include:

• Formulation improvements: Extended-release or combination therapies.
• Expansion into emerging markets: Growing healthcare infrastructure and antibiotic use.
• New indications: Investigating off-label uses, subject to regulatory approval.

However, these avenues depend heavily on clinical validation, regulatory approval, and competitive response.

---

Strategic Considerations for Stakeholders

Pharmaceutical companies must navigate patent expiries and rising antimicrobial resistance by investing in R&D for next-generation doxycycline analogs. Regulatory agencies should balance antimicrobial stewardship with patient access, ensuring responsible use without impairing therapeutic options. Healthcare providers need ongoing education regarding resistance patterns and appropriate prescribing to sustain DORYX’s relevance.

Market access strategies such as formulary positioning, payer negotiations, and patient assistance programs remain vital to preserve and grow DORYX's market footprint amid generic competition.

---

Conclusion

DORYX's market dynamics are shaped by a confluence of factors—generic competition, antimicrobial resistance, regulatory policies, and evolving clinical guidelines. Its financial trajectory appears challenged unless significant product innovation or strategic repositioning occurs.

Pharmaceutical stakeholders must focus on maintaining efficacy through R&D, optimizing cost structures, and exploring new indications. The future of DORYX hinges on adaptive strategies aligned with global health priorities to sustainably capitalize on its clinical utility.

---

Key Takeaways

• DORYX faces intense generic competition and declining revenues post-patent expiration.
• The rise of antimicrobial resistance demands innovation and adaptation in the doxycycline market.
• Formulation improvements and new indications are critical to extending DORYX's market life.
• Cost management and strategic market access are vital amid slim margins.
• Ongoing regulatory and stewardship policies influence prescribing patterns and sales performance.

---

Frequently Asked Questions (FAQs)

1. What are the primary drivers of DORYX’s declining sales?
Patent expiries, increasing generic competition, and antimicrobial resistance have reduced DORYX's prescribing volumes and profit margins.

2. How does antimicrobial resistance impact DORYX’s future prospects?
Rising resistance diminishes doxycycline’s efficacy, prompting guideline shifts and potentially reducing its clinical utility, thus constraining future sales.

3. Are there ongoing efforts to develop new formulations of DORYX?
Yes, pharmaceutical companies explore extended-release and combination formulations to enhance performance and differentiate products.

4. Can expanding indications boost DORYX’s revenues?
Potentially, if new, approved indications demonstrate efficacy and safety, opening additional patient segments.

5. What strategic steps can Pfizer take to sustain DORYX's market relevance?
Investing in R&D, pursuing formulation innovations, exploring new indications, and establishing strong market access strategies are essential actions.

---

References

[1] FDA Product Labeling for Doxycycline Hyclate (DORYX), 2022.
[2] IQVIA Data, Global Antibiotics Market Reports, 2022.
[3] WHO Global Antimicrobial Resistance Surveillance System (GLASS), 2022.
[4] Pfizer Annual Reports, 2021-2022.
[5] MarketWatch reports on antibiotic market dynamics, 2022.